CSI Market
Sign In | Register

Passage Bio Inc (PASG) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PASG quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Passage Bio Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-45.52
Depreciation & amortization0.73
Amortization of Other Assets0.13
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges6.15
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation3.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Change In Fair Value Of Future Tranche Right Liability-
Increase Decrease In Deferred Rent-
Research And Development Asset Acquired Other Than Through Business Combination Written Off-
Increase Decrease In Prepaid Research And Development0.39
Gain Loss On Termination Of Lease-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable, Trade1.88
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-2.05
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.23
Other Working Capital0.00
Other Noncash Expense0.01
Other net0.00
Payments for (Proceeds from) Other Operating Activities3.55
Discontinued operations0.00
Net Cash flow from Operating Activities-31.51
Investing Activities
Capital Expenditures0.00
Sale of Capital Items1.17
Proceeds from Sale and Maturity of Marketable Securities39.05
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Sale Of Property And Equipment And Other Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities40.22
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.02
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Deferred Offering Costs In Accrued Expenses And Other Current Liabilities-
Deferred Offering Costs In Accounts Payable-
Reclassification Of Deferred Offering Costs Paid In Prior Period-
Property And Equipment In Accounts Payable-
Vesting Of Early Exercise Option Awards-
Payments For Insurance Premium Financing-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.02
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-30.34
Total Cash Flow8.73
4 historic quarters locked

Sign in to unlock the full Passage Bio Inc cash flow history.

Sign In Create Free Account

About Passage Bio Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-022549

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License